BNP PARIBAS FINANCIAL MARKETS - RECRO PHARMA INC ownership

RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 70 filers reported holding RECRO PHARMA INC in Q4 2020. The put-call ratio across all filers is 1.67 and the average weighting 0.0%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of RECRO PHARMA INC
ValueSharesWeighting
Q3 2023$121
-57.2%
2570.0%0.00%
Q2 2023$283
-7.5%
2570.0%0.00%
Q1 2023$306
-35.2%
257
-18.9%
0.00%
Q4 2022$472
-99.9%
3170.0%0.00%
Q3 2022$517,000
+105.2%
3170.0%0.00%
Q2 2022$252,000
-55.9%
3170.0%0.00%
Q1 2022$571,000
+5.4%
3170.0%0.00%
Q4 2021$542,000
-17.0%
3170.0%0.00%
Q3 2021$653,000
-95.4%
317
-94.8%
0.00%
Q2 2021$14,079,000
+14.8%
6,095
+38.6%
0.00%
Q1 2021$12,265,000
+10.4%
4,396
+12.7%
0.00%
Q4 2020$11,112,000
+7.5%
3,899
-20.8%
0.00%
Q3 2020$10,334,000
+231.5%
4,921
+618.4%
0.00%
Q2 2020$3,117,000
-93.7%
685
-88.8%
0.00%
Q1 2020$49,853,000
-8.5%
6,102
+105.2%
0.00%
Q4 2019$54,513,000
+69.0%
2,974
+2.2%
0.00%
Q3 2019$32,254,000
+57.0%
2,911
+44.1%
0.00%
Q2 2019$20,543,000
-6.6%
2,020
-46.2%
0.00%
Q1 2019$21,987,000
+60975.0%
3,752
+74940.0%
0.00%
Q4 2018$36,000
-99.1%
5
-99.1%
0.00%
Q3 2018$4,181,000
+41.6%
5880.0%0.00%
Q2 2018$2,952,000
-90.8%
588
-79.8%
0.00%
Q1 2018$32,017,000
-6.2%
2,908
-21.2%
0.00%
Q4 2017$34,132,000
+186.0%
3,690
+177.7%
0.00%
Q3 2017$11,934,000
+19.0%
1,329
-6.9%
0.00%
Q2 2017$10,032,000
-91.7%
1,427
-85.7%
0.00%
Q3 2015$120,300,000
-6.9%
10,0000.0%0.00%
Q2 2015$129,200,00010,0000.00%
Other shareholders
RECRO PHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Samjo Capital LLC 8,039,100$3,770,3381.48%
First Light Asset Management, LLC 19,676,396$9,228,2300.88%
AWM Investment Company, Inc. 10,266,144$4,814,8220.71%
Caligan Partners LP 1,689,768$794,1910.36%
HighMark Wealth Management LLC 484,985$227,4580.19%
Nantahala Capital Management 1,250,000$586,2500.05%
Clear Harbor Asset Management, LLC 938,847$440,3190.05%
DRIEHAUS CAPITAL MANAGEMENT LLC 4,249,229$1,992,8880.03%
TITLEIST ASSET MANAGEMENT, LLC 210,148$98,5590.02%
ROYCE & ASSOCIATES LP 3,285,082$1,540,7030.02%
View complete list of RECRO PHARMA INC shareholders